Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

This phase II/III, double-blind, randomized trial assessed the efficacy, immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in young Chinese women (ClinicalTrials.gov registration NCT00779766). Women aged 18–25 years from Jiangsu province were randomized (1:1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng-Cai, Chen, Wen, Hu, Yue-Mei, Hong, Ying, Li, Juan, Zhang, Xun, Zhang, Yi-Ju, Pan, Qin-Jing, Zhao, Fang-Hui, Yu, Jia-Xi, Zhang, Yan-Shu, Yang, Xiaoping, Zhang, Cheng-Fu, Tang, Haiwen, Zhang, Helen, Lebacq, Marie, David, Marie-Pierre, Datta, Sanjoy K, Struyf, Frank, Bi, Dan, Descamps, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Infectious Causes of Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277330/
https://www.ncbi.nlm.nih.gov/pubmed/24740596
http://dx.doi.org/10.1002/ijc.28897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277330/
https://www.ncbi.nlm.nih.gov/pubmed/24740596
http://dx.doi.org/10.1002/ijc.28897

Ejemplares similares